Skip to main content

One-Third of Cancer Patients Have a Genetic Profile Accessible by Their Oncologist

By May 24, 2016December 20th, 2021No Comments

Informing the pharmaceutical drug development, manufacturing and commercialization industry.

Cary, NC – May 24, 2016 – A new market research report titled Personalized Medicine’s Effect on Oncologists’ Treatment Regimens, from Industry Standard Research (ISR), finds that, according to US-based oncologists, currently one-quarter of patients are treated using genetic tumor profiling to inform treatment decisions and this is expected to increase over the next three years. This comes on the heels of the US precision medicine initiative whereby the NIH is to collect data from at least 1M people by 2019.

“Personalized or precision medicine has been around for a while and given recent advancements and announcements, ISR wanted to understand how US oncologists are using genetic information to make treatment decisions,” explained Andrew Schafer, President at ISR.  “The results are quite fascinating, especially when we analyzed the data based on where the oncologist works (e.g. academic medical center, hospital, or private practice) and their level of experience (e.g. years post-residency and age).”

In addition to findings on increased interest in using more genetic tests and techniques, the report includes key statistics on what is preventing more widespread use of genetic testing as well as how this impacts participation in clinical trials.

“There are certainly different approaches to personalized medicine and the use of genetic testing as a means to inform treatment options. For example, only 3% of US oncologists indicated they ask all of their patients if they would like a genetic profile completed,” continued Schafer.

This report provides insights into which specific tests are currently being administered and which are likely to be administered three years from now. Specific tests included in the research are: IHC of tumor infiltrating leukocytes (TILs), flow analysis of immune cell subsets, CD8+ T-cell effectors, or immune suppressive T-reg cells, whole exome sequencing using NGS to enumerate tumor neoantigens, and circulating tumor cell or cell free DNA testing to detect, measure and characterize minimal residual disease (MRD) or guide next rounds of treatment.

For more information on ISR’s “Personalized Medicine’s Effect on Oncologists’ Treatment Regimens” report, please visit ISR’s report page.

About Industry Standard Research

Industry Standard Research is the premier, full service market research provider to the pharma and pharma services industries. With over a decade of experience, ISR delivers an unmatched level of domain expertise. For more information about ISR’s off-the-shelf intelligence and custom research offerings, please visit the company’s website at, email or follow ISR on Twitter @ISRreports.